CHALLENGE RULES

Eligibility 

The iNext Pitching Competition is open to:

•     Academic labs based in North America or Europe (including UK and Switzerland)
•     Biotech based in North America or Europe (including UK and Switzerland)

Projects must have a translational approach; basic science proposals will not be considered for review. 

We are looking for approaches or platforms that can be directly applied and does not require basic proof of concept experiments. However, we favor early stage projects that have a clearly defined mechanism of action that is in convergence with our theme.

 

Details of the funding offered by Sanofi iNext

Up to 3 winners (either vaccine approach and/or therapeutic approach)

Up to USD $ 500,000 per project

Project duration up to 18 months

For projects in Europe, the funding will be provided in local currency equivalent to $500,000. 

 

Please confirm that you have discussed the following line items with your institutions’ TTO and/or business unit and they/you agree with the statements:

If selected, my company/university will collaborate with Sanofi during the 18-month iNext funding

If selected, my company/university agrees to allow Sanofi a 30-day review prior to submittal of any outputs of this funding (i.e., publications, etc.)   

If selected, third-party involvement will be pre-negotiated between my company/university and the third party prior to signing the iNext funding contract.

Receipt of the iNext funding is contingent on my company/university completing the various contracting stages (research plan development, initial contract redlines, contract signing) within the Sanofi contracting timeline